MBX Biosciences, Inc. Common Stock (MBX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.78B
Last updated: Nov 17, 2026 at 11:06 AM ET
MBX Biosciences, Inc. Common Stock (MBX) Competitors
The companies most similar to MBX Biosciences, Inc. Common Stock are Legend Biotech (LEGN), Xencor (XNCR) and Beam Therapeutics (BEAM). By market cap, MBX Biosciences, Inc. Common Stock ranks 7th of the 13 companies on this page; Xenon Pharmaceuticals (XENE) is the largest at $3.98B.
Peer Comparison
MBX's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| MBX Biosciences, Inc. Common Stock (MBX) | $2.78B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Legend Biotech Corp (LEGN) | $3.39B | 266.5x | 2.3x | -0.0% | N/A | 32.0% | 0.00% |
| Xencor Inc (XNCR) | $2.78B | N/A | 13.5x | -58.8% | -17.3% | 454.9% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Xenon Pharmaceuticals Inc (XENE) | $3.98B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Disc Medicine Inc. (IRON) | $3.64B | N/A | N/A | 0.0% | -40.0% | 0.0% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $3.14B | N/A | 5.3x | 3.8% | -0.7% | 22.3% | 0.00% |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | $1.90B | N/A | 168.0x | 0.0% | -104.3% | -100.0% | 0.00% |
| Harmony Biosciences Holdings (HRMY) | $1.98B | 9.6x | 1.9x | 18.0% | 13.7% | 12.3% | 0.00% |
| Dyne Therapeutics Inc (DYN) | $3.22B | N/A | N/A | 0.0% | -42.9% | 0.0% | 0.00% |
| Arcus Biosciences Inc (RCUS) | $2.51B | N/A | 21.5x | 0.0% | -75.9% | -65.4% | 0.00% |
| Celldex Therapeutics Inc (CLDX) | $2.26B | N/A | N/A | 0.0% | N/A | -97.0% | 0.00% |
| Replimune Group Inc (REPL) | $2.08B | N/A | N/A | 0.0% | -65.4% | 0.0% | 0.00% |
| Peer median | $2.65B | 138.0x | 13.5x | 0.0% | -40.0% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to MBX Biosciences, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Legend Biotech Corp (LEGN) | Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology... | LEGN competitors |
| Xencor Inc (XNCR) | Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed... | XNCR competitors |
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
| Xenon Pharmaceuticals Inc (XENE) | Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders... | XENE competitors |
| Disc Medicine Inc. (IRON) | Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development... | IRON competitors |
| Telix Pharmaceuticals Limited (TLX) | Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic... | |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based... | ZBIO competitors |
| Harmony Biosciences Holdings (HRMY) | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. | HRMY competitors |
| Dyne Therapeutics Inc (DYN) | Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases... | DYN competitors |
| Arcus Biosciences Inc (RCUS) | Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. | RCUS competitors |
| Celldex Therapeutics Inc (CLDX) | Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment... | CLDX competitors |
| Replimune Group Inc (REPL) | Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts. | REPL competitors |
Frequently Asked Questions About MBX
Who are MBX Biosciences, Inc. Common Stock's main competitors?
The companies most similar to MBX Biosciences, Inc. Common Stock include Legend Biotech (LEGN), Xencor (XNCR), Beam Therapeutics (BEAM), Xenon Pharmaceuticals (XENE) and Disc Medicine (IRON), listed from the closest match.
Who is MBX Biosciences, Inc. Common Stock's biggest competitor?
Xenon Pharmaceuticals (XENE) is the largest of the similar companies at $3.98B; Legend Biotech (LEGN) is the closest match by business profile, size, sector and industry.
How does MBX stock compare with its competitors?
MBX's net margin is 0.0% against a peer median of 0.0%.
Which of MBX Biosciences, Inc. Common Stock's competitors pays a higher dividend?
MBX Biosciences, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is MBX Biosciences, Inc. Common Stock bigger than its competitors?
No. MBX Biosciences, Inc. Common Stock is 7th by market cap among the 13 companies on this page; the largest is Xenon Pharmaceuticals (XENE) at $3.98B.
MBX pages: Overview, Earnings, Forecast, Financials, Competitors